@entity1149 ( @entity1149 ) is the leading cause of @entity5 deaths. @entity3866 is the first-generation epidermal growth factor receptor- @entity4149 kinase inhibitors ( @entity470 -TKIs), the National @entity5 Network (NCCN) guidelines recommend it as a first-line agent in @entity1 with sensitizing @entity470 mutations.We conducted a meta-analysis to compare the efficacy of @entity3866 and chemotherapy for advanced @entity1149 , and evaluated the efficacy of them to provide references for further clinical practice and research.PubMed, EMBASE, CBM, CNKI, WanFang database, The Cochrane library, and Web of Science, as well as abstracts presented at ASCO conferences and ClinicalTrials.gov were searched to identify relevant studies. HR with 95% confidence intervals (CIs) for progression-free survival (PFS) and @entity1349 ( @entity1349 ), relative risk (RR) with 95% CIs for objective response rate (ORR) and 1-year survival rate (OSR) were all extracted. If the I was  <=40%, then the trial was considered to be heterogeneous, and a fixed-effects model was selected. Otherwise, a random-effects model was used. Meta-regression and sensitivity analyses were conducted to determine the possible heterogeneity causes and to further identify the influence of the various exclusion criteria on the overall risk estimate.The pooled analysis demonstrated a PFS HR of 0.93 (95% CI=0.73, 1.19) for @entity3866 versus chemotherapy and an ORR of 18.43% versus 22.07%, respectively. The @entity1349 HR was 1.02 (95%CI=0.93, 1.12). The HRs for PFS estimated based on 10 trials involving 1101 @entity1 were 0.22 (95% CI=0.15, 0.29) and 1.27 (95% CI=1.04, 1.48) in @entity470 mutation-type and wild-type @entity1 , respectively. The HRs for @entity1349 calculated from 4 studies including 681 @entity1 were 0.83 (95% CI=0.61, 1.05) and 0.86 (95% CI=0.68, 1.04) in @entity470 mutation-type and wild-type @entity1 , respectively. The 1-year survival rates were 31.31% and 32.41%, respectively.Overall, the present meta-analysis suggested that @entity3866 did not improve the ORR, PFS, @entity1349 or the 1-year survival rate for whole @entity1 . However, @entity3866 could benefit @entity1 with @entity470 mutation in terms of PFS, but the @entity1349 does not benefit from it for these @entity1 . Further studies of @entity3866 for these subgroup @entity1 are warranted.

The Efficacy of XXXX Versus Conventional Chemotherapy for @entity1149 : A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-Analysis.

@entity1 :: ('9606', 'Species') :: ['participants', 'patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'Comprehensive Cancer'] @entity470 :: ('1956', 'Gene') :: ['EGFR'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'Non-small-cell lung cancer'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine'] @entity3866 :: ('MESH:C400278', 'Chemical') :: ['erlotinib', 'Erlotinib']
@entity3866 :: (MESH:C400278,Chemical) :: ['Erlotinib']
